Algiax Pharmaceuticals GmbH is an independent biotechnology company that was established in April 2011. It is dedicated to the discovery and development of innovative products in the field of nervous system disease or dysfunction with a strong focus on neuropathic pain. The company is financially stable having raised 4,3 million Euro’s in Series A financing from a consortium of private and state-backed investors.
Funding Rounds (1) - $5.48MUpdate
Current Team (4)Update
|May 16, 2012||FinSMEs - FinSMEs|